Condition: Recurrent Supratentorial Glioblastoma · Sponsor: Darell Bigner
The purpose of this research study is to determine the safety and efficacy of administering two doses of lerapolturev in residual disease (within tumor margins) after surgery, followed later by repeated injections of lerapolturev in the subcutaneous area (under the skin) around the lymph nodes of the head and neck for adult patients diagnosed with recurrent glioblastoma at the Preston Robert Tisch Brain Tumor Center (PRTBTC) at Duke.
This description comes directly from the study's public registry record.
Madison Shoaf, MD · 919-684-5301 · dukebrain1@dm.duke.edu
Stevie Threatt · 919-684-5301 · dukebrain1@dm.duke.edu
Always discuss trial participation with your own doctor first.
| Duke University Medical Center | Durham, North Carolina, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06177964